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Abbreviations 
ARC – adenosine analogue-oligoarginine conjugate 
ATP – adenosine-5’-triphosphate 
BSA – bovine serum albumin 
cAMP – 3'-5'-cyclic adenosine monophosphate 
DDT – dithiothreitol, (2S,3S)-1,4-bis(sulfanyl)butane-2,3-diol 
FRET – Förster resonance energy transfer  
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HTS – high-throughput screening 
IC50 – half-maximal inhibitory concentration 
KD – dissociation equilibrium constant in direct binding assay 
Kd – dissociation equilibrium constant in displacement assay 
PKA – cAMP-dependent protein kinase 
PKAc – catalytic subunit of the cAMP-dependent protein kinase  
SD – standard deviation 
TGL – time-gated luminescence 
TR-FRET – time-gated FRET 
UV-Vis – ultraviolet-visible 
Z-factor – screening window coefficient 
ε – molar extinction coefficient 
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1. Introduction 
Measurements of biochemical analytes are often difficult due to complicated matrixes and 
instability of substances. Nevertheless, these analyses are important for the development of 
biomedical research tools and drugs. 
The disadvantageous aberrant activity of protein kinases has triggered an increasing need for 
reliable methods for characterizing the inhibitors of protein kinases. In the medicinal chemistry 
research group at the Institute of Chemistry of University of Tartu different variety of 
bisubstrate inhibitors called ARCs for protein kinases have been developed. Based on ARCs 
novel photoluminescent probes have been constructed that have found applications in screening 
and characterization of kinases, but also in methods for evaluating the affinity of new inhibitors.  
Time-resolved photoluminescence method based on the application of ARC-Lum probes is a 
high-throughput screening assay that combines several advantages of using Förster resonance 
energy transfer induced signal amplification together with time gated measurements. This 
method can be used to determine the affinity of protein kinase inhibitors that bind to the binding 
sites of ATP and/or substrate. The responsiveness of the luminescence signal to the presence 
of the target protein enables the realization of the assays in biological matrixes without any 
significant interference. 
The purpose of this work was to determine the optimal conditions for ARC-Lum based time-
resolved photo-luminescence method for affinity analysis of inhibitors with different properties. 
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2. Literature Overview 
2.1. Protein Kinases 
Protein kinases catalyze the transfer of the γ-phosphoryl group from adenosine-5’-triphosphate 
(ATP) to a serine, threonine or tyrosine residue of a protein substrate. With this simple chemical 
reaction, the structure of a protein substrate is modified and consequently, the intercellular 
communication is affected. The latter, in turn, is related to physiological responses, like 
homeostasis, function of the nervous and immune system (Manning et al. 2002). However, the 
aberrant activity of protein kinases is related to many human diseases, for instance cancer, 
diabetes, rheumatoid arthritis, hypertension, schizophrenia and obesity (Hanks & Hunter 1995, 
Manning et al. 2002).  
There was a prediction made about 27 years ago that the human genome includes 1001 protein 
kinases (Hunter 1987) and five years later even a larger number was proposed (Hunter 1994). 
Since then, the scientists have made remarkable contributions to identify all of the human 
protein kinases. In 1988, approximately 100 protein kinases had been identified (Hanks et al. 
1988). The number reached 538 in 2011, constituting about 2% of 23000 human genes 
(Schwartz & Murray 2011). Protein kinases are classified into eight main groups, based on the 
amino acid sequence similarity of the catalytic domain. (Hanks & Hunter 1995, Manning et al. 
2002). 
A thoroughly examined protein kinase, the cAMP-dependent protein kinase (PKA) from AGC 
group, was identified in 1968 (Walsh et al. 1968). PKA is a serine/threonine-specific kinase, 
omnipresent in human cells, that is responsible for enforcement of a large number of 
intracellular signaling events. At its inactive state PKA is a heterotetrameric holoenzyme that 
comprises a regulatory subunit dimer and two catalytic subunits (PKAc) (Krebs & Beavo 1979). 
The binding of 2 molecules of 3'-5'-cyclic adenosine monophosphate (cAMP), which is an 
important second messenger in the cell, to a regulatory subunit leads to a conformational 
change of the protein complex. Consequently, the PKA holenzyme is dissociated into a 
regulatory subunit dimer and two active catalytic subunits, PKAc (Anand et al. 2010, Kim et 
al. 2005, Sjoberg et al. 2010).  
Despite of the importance of protein kinases in cell life, only a very small portion of them are 
targeted with the drugs that have reached the clinic (Schwartz & Murray 2011). The reason for 
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that lies in the problem that  the role of many protein kinases in cell life has not been 
established yet  (Fedorov et al. 2010). For this reason, there is a high need for reliable methods 
and well characterized inhibitors and probes that would enable tracking the localization and 
regulation the activity of protein kinases in cells. 
2.2. Inhibitors of Protein Kinases 
As mentioned before, protein kinases regulate a large number of cellular processes, and the 
over-expressed kinases have pathological consequences. To solve this problem, the field of 
drug development activities related to inhibitors of protein kinases is constantly increasing. 
Among all types of the inhibitors of protein kinases, including antibodies, small molecule 
inhibitors have been preferably chosen for drug research as they inhibit the abnormal activity 
of protein kinases directly. Although the majority of mentioned studies are focused on 
oncology, more and more clinical trials have been carried out for the treatment of other diseases, 
for example, the treatment of inflammatory diseases (Cohen & Alessi 2013).  
The selective inhibitors with suitable  optical properties can also be used as probes to study 
different intracellular and extracellular enzymes (Cravatt et al. 2008), e.g. for the determination 
of activity and location of protein kinases (Kasari et al. 2012, Vaasa et al. 2012). Furthermore, 
such probes can also be used to characterize the irreversible inhibitors (Barf & Kaptein 2012).  
There are some general requirements for an ideal inhibitor, either it is used as a probe or as a 
potential drug. First, the inhibitors should block substrate binding sites of protein kinases. 
Second, inhibitors should have a good selectivity. At last, they should have high bioavailability 
and low toxicity (Parang & Cole 2002).  
According to the inhibitor’s targeting site at the catalytic domain of protein kinase, the 
inhibitors can be classified into four types: ATP-competitive inhibitors, protein/peptide- 
competitive inhibitors, bisubstrate inhibitors and allosteric inhibitors (Bogoyevitch & Fairlie 
2007).  
2.2.1.  ATP-Competitive Inhibitors 
ATP-competitive inhibitor is an inhibitor which inhibits the protein kinase by targeting the 
ATP-site of the catalytic domain (Bridges 2001, Lawrence & Niu 1998, Lindsley et al. 2007). 
Although the majority of protein kinase inhibitors that have been characterized belong to this 
group, the development of small and selective ATP-site inhibitors faces two major challenges: 
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selectivity and potency. It has been challenging to develop kinase inhibitors that can inhibit 
only one of the 538 protein kinases which have rather similar ATP-binding pockets (Bain et al. 
2003, Bain et al. 2007, Davies et al. 2000). Furthermore, the inhibitor, which targets the ATP-
binding site of the kinase, needs to have a sufficient potency to compete with the high 
(millimolar) concentration of ATP present in the cell (Gribble et al. 2000).  
Nevertheless, a number of ATP-competitive protein kinase inhibitors have been approved by 
U.S. Food and Drug Administration, for example: erlotinib, gefitinib and imatinib (Kondapalli 
et al. 2005). The latter, for example, has high inhibitory potency towards a limited number of 
kinases and thus can be used for the treatment of chronic myelogenous leukemia, 
gastrointestinal tumors and myeloproliferative diseases (Cohen & Alessi 2013). 
2.2.2. Protein/Peptide-Competitive Inhibitors 
As the binding sites of protein/peptide substrates differ from kinase to kinase, the 
protein/peptide-competitive inhibitors have relatively higher selectivity compared to ATP-
competitive inhibitors (Bogoyevitch et al. 2005). Furthermore, the affinity of protein/peptide-
competitive inhibitors is enhanced at a high concentration of ATP due to the positive 
cooperativity when the ATP-site is occupied (Masterson et al. 2008).  
One of the disadvantages that protein/peptide-competitive inhibitors often possess is the low 
stability of the compounds due to the presence of proteases in the cellular environment. 
Furthermore, peptide-based protein substrate-competitive inhibitors are longer structures in 
order to achieve high inhibitory potency (Bogoyevitch et al. 2005). This, on the other hand, 
may cause problems of absorption, distribution and toxicity (Zhao & Tang 2007). Fortunately, 
the “hot-spot” theory solved this problem. This theory revealed that only small number of 
peptide residues contribute to the binding energy (London et al. 2010, Bogan & Thorn 1998). 
This was a discovery that enhanced the development of small molecule substrate 
protein/peptide-competitive inhibitors.  
2.2.3. Bisubstrate Inhibitors 
Bisubstrate inhibitor, just as its name implies, is an inhibitor, which inhibits protein kinases by 
blocking the binding sites of ATP and protein/peptide simultaneously. It aims to overcome the 
common shortcomings of ATP and protein/peptide-competitive inhibitors (Hines & Cole 2004, 
Lavogina et al. 2010, Parang & Cole 2002, Parang et al. 2001, Ricouart et al. 1991, Schneider 
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et al. 2005). However, bisubstrate inhibitors also combine some drawbacks of these two type 
of inhibitors such as high molecular mass, which results in low bioavailability, and low stability 
of the peptide moieties (Lavogina et al. 2010). The latter problems can be solved by 
incorporating structure elements that can improve the cell plasma membrane penetration 
properties and proteolytic stability (Kayser et al. 2007, Kayser-Bricker et al. 2009).  
2.2.3.1. Adenosine Analogue-Oligoarginine Conjugates  
According to the requirements for bisubstrate inhibitors, the medicinal chemistry research 
group of the Institute of Chemistry (University of Tartu) has developed several compounds 
called the adenosine analogue-oligoarginine conjugates (ARCs) (Loog et al. 1999). The 
adenosine mimic, targeting the ATP-binding site, and the arginine-rich peptide, targeting the 
protein/peptide-binding site, are joined together with a flexible linker (Figure 1.).  
 
Figure 1. An example of an ARC-based inhibitor (Vaasa et al. 2009) 
During 15 years, different generations of ARCs have been developed, mainly for inhibiting the 
basophilic protein kinases. When the first ARCs contained L-arginines, a 6-aminohexanoic acid 
as a linker and had sub-micromolar affinity towards PKAc (Enkvist et al. 2006, Loog et al. 
1999), then the latest ARCs include D-amino acid residues, two linkers with a chiral spacer, 
possess picomolar affinities and enhanced proteolytic stability (Lavogina et al. 2010, Lavogina 
et al. 2009, Vaasa et al. 2009). A number of ARCs have been labeled with a fluorescent dye, 
which enables to use them as optical probes in different applications: e.g. testing of new 
compounds towards biologically important targets like protein kinases (Vaasa et al. 2009), 
mapping of protein kinases in living cells (Vaasa et al. 2010). Fluorescently labeled ARCs 
containing a thiophene or a selenophene moiety were introduced in 2011 (Enkvist et al. 2011). 
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These ARC-Lum probes have the unique property to give long-lifetime luminescence emission 
when bound to protein kinases. The discovery of this phenomenon expanded the applications 
of ARCs even more (Kasari et al. 2013, Vaasa et al. 2012). 
2.3. Luminescence-Based Methods for Characterizing Inhibitors 
Characterization of inhibitors of protein kinases is of crucial importance for the development 
of biomedical research tools and drugs. Consequently, the need for reliable high-throughput 
screening (HTS) methods is continuously increasing.  
Inhibition of enzymatic phosphorylation, homogeneous direct binding and displacement assays 
are the most frequently used methods for characterization of inhibitors of protein kinases. In 
the inhibition assay, the velocity of product formation or the final concentration of the product 
is observed with and without the presence of the inhibitor (Kuznetsov et al. 2004). However, 
inhibition assays require at least both donor (ATP) and acceptor (peptide substrate) of 
phosphoryl group. In some assay setups, radioactively labeled phosphoryl group is used, which 
is hazardous to humans and the environment.  
In contrast, the homogeneous direct binding or displacement assay formats do not require 
phosphoryl group donor and acceptor. Instead, a fluorescently labeled inhibitor (a probe) could 
be used (Viht et al. 2005). The signal emitted by the probe is different if it is free or bound to 
the kinase. In case of direct binding assay, the labeled compound is characterized by observing 
the binding to the protein kinases directly (Vaasa et al. 2009). The displacement binding, on 
the other hand, is usually applied for the determination of properties of unlabeled inhibitors by 
displacing the labeled probe from the complex with a protein kinase (Enkvist et al. 2012). Due 
to the low consumption of reagents, high sensitivity and applicability in HTS, luminescence is 
becoming a dominant technique used in binding assays (Uri et al. 2010). 
2.3.1. Principles of Photoluminescence 
The light emitted from electronically excited states by substances is called luminescence. There 
are two subtypes of luminescence differenced by the nature of the excited state – 
phosphorescence and fluorescence (Figure 2). When a rigid molecule absorbs electromagnetic 
radiation (UV radiation or light), an electron is excited from the ground singlet state (S0) to a 
higher singlet state (S1 or S2). After that, the excited electron rapidly returns to the lowest 
vibrational level of S1. This is called an internal conversion, which is a non-radiative process. 
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In a case of some molecules, if an electron reaches to the ground state, fluorescence is emitted 
during ~10-8 seconds (Lakowicz 2006). In case of phosphorescence, after the absorption of 
electromagnetic radiation and excitement of the electron, the latter is transited from S1 to the 
first triplet state (T1) through singlet-triplet intersystem crossing. During the relaxation from 
T1 to S0, phosphorescence with a considerably longer lifetime (approximately milliseconds) is 
emitted.  
 
Figure 2. Principles of fluorescence and phosphorescence. S0, S1, S2 and T1 denote as the singlet ground, first 
electronic state, second electronic state and first triplet state, respectively (Lakowicz 2006).           
Based on the principles of fluorescence and phosphorescence four measurement methods are 
introduced: fluorescence anisotropy (FA), time-gated luminescence (TGL), Förster resonance 
energy transfer (FRET), and time-resolved FRET (TR-FRET)1.                                                                                                                                                                              
2.3.2.  Fluorescence Anisotropy 
FA assay enables the investigation of interactions between molecules, e.g. a probe and a kinase  
(Ehrlich et al. 2011). In FA assay the sample is excited by a linearly polarized light. For 
detection, the emitted light is directed through a parallel and a perpendicular polarizer (with 
respect to the incident light). Accordingly, the equation of FA is defined (Equation 1). 
  
                                                          
1 Although “time-gated” and “time-resolved” have a similar meaning, the first is usually used together with the 
term “luminescence”, and the latter with “FRET”. 
hνF
Intersystem CrossingS
S0
S2
Internal Conversion
Fluorescence
Phosphorescence
T1
hνA hνP
S1
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𝐹𝐴 =
𝐼ІІ − 𝐼⊥
𝐼ІІ + 2𝐼⊥
 
Equation 1. Fluorescence anisotropy equation (Lakowicz 2006). III and I⊥ are parallel and perpendicularly 
polarized fluorescence intensities, respectively, in the condition where the sample is excited with vertically 
incident light. 
Due to the small molecular weight (usually less than 3 kDa), the free fluorescence probe rotates 
several times within the fluorescence lifetime of a fluorophore (Lakowicz 2006). This results 
in depolarization of the emitted light, giving roughly the same intensities in both of the angular 
directions and therefore a small value for fluorescence anisotropy (Lakowicz 2006). If the 
probe-kinase complex is formed, the rotational tumbling of the fluorophore is reduced as the 
kinase (MW >30 kDa) has substantially longer rotational correlation time. Slower rotation of 
the fluorophore due to the binding causes the III to increase and I⊥  to decrease, resulting in 
higher value of fluorescence anisotropy. 
Although fluorescence anisotropy is a powerful method often used in the biological and 
biophysical fields (Ehrlich et al. 2011), there are two disadvantages. First, one has to be 
cautious using this method with complicated solutions, e.g. containing non-target proteins at 
high concentrations (cell lysates, bodily fluids). For example, there might be non-specific 
binding of the probe to other components, which results in nonspecific anisotropy increase. 
Additionally, if a low-affinity probe is used in displacement assays, a high concentration of the 
kinase is needed, which is costly. The higher concentration of the protein kinase guarantees 
that most of the molecules of the probe are bound to the protein kinase. Otherwise, the free 
probe would interfere with the polarization measurements. This, on the other hand, influences 
the reliability of the assay window and the determined affinity. 
2.3.3.  Time-Gated Measurements 
FRET, a phenomenon, which was described by Theodor Förster in 1946, is an energy transfer 
between two fluorescent molecules which occurs if the excitation spectrum of the acceptor 
chromophore overlaps with the emission spectrum of the donor fluorophore (Förster 1946). If 
these two chromophores are close enough (1-10 nm) (Figure 3), the excitation of the donor at 
the lower wavelength energy source triggers the energy transfer to the acceptor, which results 
in the enhanced emission at the higher wavelength of the acceptor (Arai & Nagai 2013). 
Because of the requirement close distance between the donor and the acceptor fluorophores for 
efficient energy transfer, FRET-based assays are sensitive towards interactions of two 
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molecules, fast and applicable in different fields of , e.g. to study protein-protein interactions 
or to detect nucleic acids (Reischl et al. 2003, Li et al. 2008). However, the method is sensitive 
towards the substances present in biological samples that might cause background fluorescence 
(Riddle et al. 2006). 
 
Figure 3. The principle of FRET (Sourjik & Berg 2002). 
In order to overcome the problems, the combination of time-resolved methods and FRET has 
been widely used since it was first introduced (Mathis 1995). The main characteristic of time-
resolved detection method is a time delay between the excitation pulse and measurement 
window (Figure 4). The latter is possible, because the donor emits a long lifetime luminescence 
signal after excitation. Short lifetime and non-specific signal from other compounds in the 
solution will fade within the delay time. 
Figure 4. Principle of TR-FRET based assay (Enkvist et al. 2011). 
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Europium and terbium chelates  lanthanides complexes that were first used as long-lifetime 
luminescence donors (Mathis 1993). Both complexes have very long luminescence half-lives 
(300 μs to 1 ms) (Bazin et al. 2001).  
Although the employment of these probes has found successful applications (Lebakken et al. 
2009), for example in the analysis of protein kinase inhibitors, the need for several compounds 
for detection reduces the robustness and simplicity of the method. Despite many advantages, 
lanthanide-based donors have complex structures that badly penetrate cell plasma membrane 
and may be degraded in biological solutions (Didier et al. 2011). 
2.3.4. ARC-Lum Based TR-FRET Assay 
The novel ARC-Lum compounds, introduced in chapter 2.2.3.1, could be used as counterparts 
of the lanthanide-based probes. The thiophene- or selenophene-containing moiety that binds to 
the ATP-site of a protein kinase serves as the luminescence donor in the ARC-Lum probe 
(Enkvist et al. 2011) (Figure 5). Due to the fluorescent label attached to the peptide moiety of 
the probe, FRET is observed between the excited thiophene/selenophene fragment (a donor) 
and the fluorophore (an acceptor) with luminescence half-life in the range of 20 - 270 µs This 
kind of organic molecule possessing intrinsic property of inducing TR-FRET in special 
conditions is rarely encountered. 
 
Figure 5. Principle of ARC-Lum based TGL Assay. If the sample is irradiated at ~337 nm, the long lifetime 
luminescence signal at ~675 nm is produced only if the ARC-Lum probe is in complex with a kinase (Kasari et 
al. 2012). Because of the bisubstrate character ARC-Lum probes they are displaced from the complex with 
compounds binding to any domain of the active site of the enzyme. 
Responsiveness of the ARC-Lum probe is one of the main features to highlight, meaning that 
the probe will only emit the long-lifetime luminescence if in a complex with a kinase. This is 
Protein Kinase
Inhibitor
Protein Kinase
ARC-Lum
Ex. 337(50) nm 
Em. 675(50) nm
20 – 270 µs ARC-Lum
Inhibitor
No long lifetime luminescence signal
Ex. 337(50) nm 
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most probably due to the fixation of the thiophene/selenophene fragment and its effective burial 
from quenching molecular species and motional effects if positioned in the active site of the 
protein kinase. Free probe, on the other hand does not emit long-lifetime luminescence. This 
property can be thus used as an indication whether the probe has bound to the protein kinase 
or not.  
Secondly, ARC-Lum probes have both fluorescent and phosphorescent properties, thus these 
probes can be used in parallel for fluorescence anisotropy/polarization and TGL assays. Thirdly, 
ARC-Lum probes can be used displacement assays even when the analyte is an inhibitor with 
very high affinity. High concentrations of the probe can be used to shift the displacement curve 
from the tight-binding region as the free probe lacks luminescence signal and there is no 
significant background noise. What is more, some ARC-Lum probes possess very high affinity 
(~20 pM) towards PKAc, which enables lowering of its the concentrations and volumes used 
in the assays. (Kasari et al. 2013, Enkvist et al. 2011) 
2.3.5. The Affinity Characterization for Inhibitor/Ligand 
All of the previously described methods can be used to describe the interactions between an 
enzyme (e.g. protein kinase) and a ligand (e.g. an inhibitor). There is a basic interaction of 
formation of the complex between the free enzyme and free ligand in equilibrium conditions 
(Equation 2). 
 
Equation 2. Scheme of equilibrium binding. The complex (EL) between the free enzyme (E) and free ligand (L) 
in equilibrium conditions. k+1 and k-1 denote the association and dissociation rate constants, respectively. 
The equilibrium dissociation constant KD is defined as the ratio of the concentrations of free 
enzyme and free ligand to the concentration of the formed complex (Equation 3 A). KD is used 
to quantify the affinity of the ligand towards the enzyme in direct binding assay and  Kd 
denotes the displacement dissociation constant (Equation 3 B and 3 C) based on the Cheng-
Prusoff equation (Cheng & Prusoff 1973). 
  
k+1
k-1
E + L EL
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A)   𝐾𝐷 =
[𝐸][𝐿]
[𝐸𝐿]
     B)   𝐾𝑑 =
𝐼𝐶50
1+
[𝐿]
𝐾𝐷
   C)   𝐾𝑑 =
𝐼𝐶50
1+
[𝐿]50
𝐾𝐷
+
[𝑃]0
𝐾𝐷
   
Equation 3. A) Equilibrium dissociation constant, (KD), where [E] is the total concentration of the enzyme, [L] is 
the total concentration of the ligand and [EL] the concentration of the complex; B) equilibrium dissociation 
constant (Kd)  determined from the displacement assay, where IC50 refers to the concentration of a competitive 
inhibitor at the point, where 50% of the ligand is displaced from the ligand-kinase complex; C) equilibrium 
dissociation constant determined in a displacement assay, taking into account of active concentration of kinase. 
Where [L]50 and [P]50 are denoted as the concentration of the free labeled ligand at 50% inhibition and the 
concentration of the free protein at 0% inhibition respectively (Nikolovska-Coleska et al. 2004). 
2.3.6. Z-Factor 
Z-factor is a screening window coefficient which is used to estimate the assay window range 
and the data variations (Zhang et al. 1999). The Z-factor in displacement assays is defined as 
(Equation 4): 
𝑍 = 1 −
3 × 𝑆𝐷 of upper plateau values + 3 × 𝑆𝐷 of lower plateau values
mean of upper plateau values − mean of lower plateau values
 
Equation 4. The equation of Z-factor in case of displacement assay. Where the upper plateau indicates the positive 
control, where the signal is formed, and the lower plateau indicates the negative control, where there should not 
be any signal. 
The range of Z-factor is from 1 to -1. If Z = 1, SD = 0 or the distance between the upper plateau 
value and the lower plateau value is infinite, describing an ideal assay. If 1 >Z ≥ 0.5, separation 
band is large, which describes an excellent assay. If 0.5 >Z ≥ 0, separation band is small and if 
Z = 0, there is no separation band and the upper plateau and the lower plateau are not separated. 
If Z-factor < 0, there is no separation and the upper plateau value and lower plateau overlap 
with each other, which is a scenario impossible to be applied in the screening assay. In general, 
the Z-factor can be used as a parameter to validate the assay procedure, and the instrument. In 
addition, the Z-factor is also sensitive to assay conditions, for example, the chemical 
composition and the concentrations (Zhang et al. 1999). 
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3. Experimental 
3.1. Chemicals and Materials 
Chemicals used in the experiments were obtained from the following sources: human PKAc 
was produced and purified by Taavi Ivan and Jevgenia Bredihhina (Rogozina) University 
of Tromsø as previously described (Lavogina et al. 2009); bovine serum albumin (BSA), 
dithiothreitol (DTT), HEPES hemisodium salt and Tween® 20 from Sigma Life Science; 
sodium chloride from Riedel-de Haën; Bodipy FL from Invitrogen. All the solutions were made 
in MilliQ water (Millipore Corporation). 
The ARCs used in the experiments were ARC-1042, ARC-1182 (ARC-Lum), ARC-1063 
(ARC-Lum), ARC-904, ARC-1411 and ARC-1012 (Appendix 1), synthesized in the Asko 
Uri’s research group (Institute of Chemistry, University of Tartu) (Enkvist et al. 2011, Vaasa 
et al. 2009, Viira 2012). 
Assays were performed in the following buffers. 5-component buffer: 50 mM HEPES, 150 
mM NaCl, 7.5 µM or 1.5 µM BSA, 5 nM DTT, 0.005% Tween® 20, pH = 7.4. 4-component 
buffer: 50 mM HEPES, 150 mM NaCl, 5 nM DTT, 0.005% Tween® 20, pH = 7.4. 3-
component buffer: 50 mM HEPES, 150 mM NaCl, 0.005% Tween® 20, pH = 7.4. 
3.2. Equipment 
Equipment Manufacturer Supplementary information 
384-well microplates Corning Non-binding surface, code 
3676 
Centrifuge Sigma 3-16 PK; rotor: 11133 
Spectrophotometer Thermo Scientific NanoDrop 2000c 
Vortex IKA MS 3 basic 
Microplate shaker-incubator BMG Labtech THERMOstar 
Automatic 8-channel pipette INTEGRA Biosciences 5…125 µl 
Manual Pipette Eppendorf 0.1 … 2.5 µl;  
0.5 … 10 µl; 
2 … 20 µl; 
10 … 100 µl; 
20 … 200 µl; 
100 … 1000 µl 
Microplate Reader BMG Labtech PHERAstar Plus 
Detector: Photomultiplier tubes 
Lamp: Xenon flash lamp 
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The following programs were used: Prism 5.0 (Graphpad software), SPSS statistic 19.0 
(International Business Machines Corporation), Microsoft Excel 2007 (Microsoft Corporation), 
NanoDrop2000 (Thermo Scientific), ChemDraw (PerkinElmer Incorporation). 
3.3. Determination of the Concentrations of ARC-Compounds 
Solid ARCs were dissolved in the 3-component buffer. The absorption was measured with a 
spectrophotometer at absorption maximum of the UV-Vis spectrum for at least 5 times and the 
average value was used to calculate the concentration of ARC-compounds according to the 
Beer-Lambert’s equation (Equation 5). The extinction coefficients of ARC-compounds are 
reported in Table 1. The optical path length of the NanoDrop 2000c instrument was 0.10 cm. 
The concentration of the solutions of ARCs were determined before every series of 
measurements. 
𝐴𝜆 = 𝜀𝜆𝑙𝑐 
Equation 5. Beer-Lambert’s law: Aλ – absorption at wavelength λ, ε – molar extinction coefficient [M-1cm-1], λ – 
wavelength [nm], c – concentration of the solution [M], l – path length [cm]. 
Table 1. The extinction coefficients of ARC-compounds. ARC-1182 and ARC-1063 belong to the ARC-Lum 
group; [A]: (Vaasa et al. 2009); [B]: (Enkvist et al. 2011); [C]: (Viira 2012) 
Compound ε [M-1 cm-1] λ [nm] 
ARC-1042 80000 [A] 559 
ARC-904 15000 [A] 260 
ARC-1182 250000 [B] 651 
ARC-1063 250000 [B] 654 
ARC-1411 15000 [C] 286 
ARC-1012 15000 [A] 260 
 
3.4. Determination of the Active Concentration of PKAc 
The active concentration of PKAc was determined before each TGL displacement assay. The 
direct binding assay based on fluorescence anisotropy was  used as described previously 
(Vaasa et al. 2009). All the assays were performed in a 384-well microplate. The 2-fold dilution 
series of PKAc, starting from 300 nM, were made in the 5-component buffer and ARC-1042 
was added into each well at final concentration of 20 nM. The final volume in each well was 
20 µl. The microplate was incubated at 30 ºC, with simultaneous shaking at 300 rpm, for 10 
minutes and then measured with the microplate reader with fluorescence polarization optical 
module [excitation at 540 (20) nm, emission at 590 (20) nm]. At each well, three cycles of 200 
flashes per cycle was measured. The sensitivity of the detector was adjusted with 20 nM ARC-
1042 in a 5-component buffer. The anisotropy and fluorescence intensity values at each point 
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were obtained and correction factor k for the active concentration of the kinase was calculated 
using the nonlinear regression equation (Equation 6). 
𝑌 = (1 − 𝑀) × 𝐴𝑓 + 𝑀 × 𝐴𝑏 
𝑀 =
𝑄 × 𝑍
[1 + 𝑍 × (𝑄 − 1)]
 
𝑍 =
𝐿𝑡 + 𝐾𝑑 + 𝑘 × 𝑋 − √(𝐿𝑡 + 𝐾𝑑 + 𝑘 × 𝑋)2 − 4 × 𝐿𝑡 × 𝑘 × 𝑋
2 × 𝐿𝑡
 
Equation 6. The equation of anisotropy, where Y is the measured anisotropy, Af and Ab are the anisotropy values 
of the free ligand and anisotropy of the ligand in complex, respectively, Q is the ratio of the quantum yields of 
bound and free probe, Lt is the total concentration of the ligand, Kd represents the dissociation constant of the 
ligand-kinase complex, X is the total concentration of the protein kinase, k is the ratio of the active (binding) and 
the reported by the provider concentration of the protein kinase. 
3.5. Displacement Assays 
The displacement assay was used to determine the Kd value of the tested inhibitor by competing 
with the photoluminescent probe (ARC-Lum). In detail, the dilution series of the tested 
inhibitor was made with an 8-channel automatic pipette (Appendix 2) and the complex of the 
ARC-Lum and the kinase was added into very well of the dilution series. Before all of the 
measurements the microplates were incubated at 30 ºC with simultaneous shaking at 300 rpm 
for 25 minutes and then measured with the microplate reader with fluorescence polarization 
optical module [excitation at 590 (50) nm, emission at 675 (50) nm] and HTRF optical module 
[excitation at 337 (50) nm, emission at 675 (50) nm]. The anisotropy, fluorescence and TGL 
intensities were obtained from each well. The IC50 value was determined by the Equation 7, 
and the Kd was calculated using the Equation 3C. See Figure 6 as an example of a displacement 
curve.  
𝑌 = Bottom +
(Top − Bottom)
(1 + 10(Log 𝐼𝐶50−𝑋)∗Hill slope))
 
Equation 7. Nonlinear regression equation for IC50 calculation from a displacement curve, where X is a logarithm 
of the inhibitor’s concentration; Y is a response (e.g. the TGL signal), decreasing as X increases; Top and Bottom 
are the plateau values for the upper and lower plateau in same units as Y; LogIC50 is the logarithm of half maximal 
inhibitory concentration, the same log units as X; the Hill slope is the quantified steepness, also called a slope 
factor.   
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Figure 6. An example of a displacement curve. The lower plateau is formed in the displacement curve, when the 
tested inhibitor at higher concentrations is able to completely displace the probe (ARC-Lum) from the complex 
with a kinase. The ARC-Lum is thus freely in the solution and no TGL signal is produced. The lower the 
concentration of the competitive inhibitor, the lower is its capability to displace the probe from the complex with 
a kinase. Finally the higher plateau is formed, where the TGL signal is the highest. The logarithm of the half-
maximal inhibitory concentration, which indicates the quantity of the inhibitor needed to displace the probe from 
50% of the protein kinase could also be determined from the curve. 
3.6. Determination of the Suitable BSA Concentration for the Buffer 
3.6.1. Incubation Time Study 
Two displacement curves were made (as described before). Dilution series of ARC-1411 
starting from 20 µM were made and the complex of 50 nM ARC-1182 and 1 nM PKAc was 
added. The first curve was analyzed after 25 minutes of incubation. The second curve was 
analyzed after 50 minutes of incubation. 
3.6.2. The Study of the Behavior of ARC-1182 towards BSA 
Assay 1. 3-fold dilution series of 50 µM ARC-1411, 100 nM ARC-1182 and 1 nM PKAc in 5-
component buffer (7.5 µM BSA) or 4-component buffer were made. 
Assay 2. The 2-fold dilution series of BSA was made in the 4-component buffer and ARC-
1182 with final concentration of 1 nM or 100 nM was added into each dilution line of the BSA. 
Assay 3. 2 replicate points of 100 nM ARC-1182 and ARC-1063 in 4-component buffer and 
5-component buffer with 7.5 µM BSA, 50 nM ARC-1182 and ARC-1063 in 5-component 
buffer with 7.5 µM BSA were made. 
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All the microplates were incubated at 30 ºC with simultaneous shaking at 300 rpm for 25 
minutes and then measured with the microplate reader with fluorescence polarization optical 
module [excitation at 590 (50) nm, emission at 675 (50) nm] and HTRF optical module 
[excitation at 337 (50) nm, emission at 675 (50) nm] (three cycles of 200 flashes per cycle), 
respectively. The anisotropy, fluorescence and TGL intensities were measured in each well.  
3.6.3. The Determination of BSA Concentration for Assays  
The 2-fold dilution series of ARC-1182 starting from 400 nM were made in the 4-component 
buffer and BSA was added at 1.5 µM or 7.5 µM concentration into each dilution line of the 
ARC-1182. The microplate was measured at the same conditions as in chapter 3.6.2. 
3.7. Determination of the Optimal Assay Conditions and Affinity 
3.7.1. Different Conditions for the TGL Method 
In order to determine the affinities of ARC-1012, ARC-904 and ARC-1411 and optimal 
conditions for TGL based displacement measurements, different concentrations of these 
compounds, PKAc and ARC-1182 were set as different levels of full factorial assays (Table 2, 
Table 3, Table 4)2. 
Table 2. The full factorial design to determine the affinity of ARC-904. 27 different levels of TGL-based 
displacement assays were made and each level was repeated 3 times 
Compound Concentration 
level 
ARC-904 (µM) 1 4 8 
PKAc (nM) 0.1 0.5 1 
ARC-1182 (nM) 0.1 0.5 1 
 
  
                                                          
2 The concentration level for the inhibitor means the first point of the dilution series. 
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Table 3. The full factorial design to determine the affinity of ARC-1012. 27 different levels of TGL-based 
displacement assays were made and each level was repeated 3 times 
Compound Concentration 
level 
ARC-1012 (µM) 80 120 180 
PKAc (nM) 0.1 0.5 1 
ARC-1182 (nM) 0.1 0.5 1 
Table 4. The full factorial design to determine the affinity of ARC-1411. 36 different levels of TGL-based 
displacement assays were made and each level was repeated 3 times 
Compound Concentration level 
ARC-1411 (µM) 5 20 40 80 
PKAc (nM) 0.1 0.5 1  
ARC-1182 (nM) 10 40 80  
A 3-fold dilution series of the tested inhibitor (ARC-904, ARC-1012 or ARC-1411) was made 
into a buffer: in case of ARC-1411, 5-compound buffer with 1.5 µM BSA was used; in case 
of ARC-904 and ARC-1012, 5-compound buffer with 7.5 µM BSA was used. Finally, the 
complex of PKAc and ARC-1182, was added into each well. The final volume in each of the 
wells was 20 µl. All the assays were measured and analyzed as described previously in chapter 
3.5. 
3.7.2. The Parameters to Evaluate the Assay Quality  
To determine the optimal assay conditions, different parameters were taken into account for 
the evaluation (Table 5). The weightage was set intuitively, based on the importance of each 
parameter. The calculations of score of parameters are based on the Equation 8. 
Table 5. Parameters for estimating the assay conditions 
Parameter Weightage 
Relative bias of Kd value 30% 
Relative standard deviation of Kd value 15% 
Z-factor 15% 
Relative standard deviation of data points 15% 
Outliers 5% 
Financial prominence 20% 
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 Score of relative bias of Kd = [1 − relative bias of Kd] × weightage × 100 
 Score of Z − factor = Z − factor × weightage × 100 
 Score of relative SD of data points = (1 − SDDP,rel ) × weightage × 100 
 Score of outliers = (
number of outliers
2
) × weightage × 100 
 Score of relative SD of 𝐾𝑑  value = (1 − SDKd,rel  ) × weightage × 100 
Equation 8. The formulas for score calculations of parameters. 
The financial prominence was calculated based on the marketing price and the consumption of 
the compounds. The final score was calculated by the sum the score of each parameter. The 
higher the total score, the better is the quality of the assay under the studied conditions. 
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4. Results and Discussion 
The importance of the protein kinases as drug targets has caused an increasing need for reliable 
HTS methods for characterization of new compounds. The best HTS assays require small 
amount of sample, are time saving and robust, have adequate sensitivity, accuracy, precision 
and are prone for automation (Zhang et al. 1999). Based on these requirements, the aim of this 
work was to determine the optimal conditions for previously introduced ARC-Lum based TGL 
method for determination of affinities of different inhibitors of PKAc by analyzing trueness, 
precision, screening window coefficient, outliers and economical contribution. 
4.1. Determination of the Effect of BSA 
ARC-1411 is a very high affinity inhibitor towards PKAc. In order to establish the exact 
affinity of the probe with ARC-Lum based TGL method, high concentration of ARC-1182 (the 
probe) was required to shift the IC50 value (see Equation 3 B) to avoid the tight binding 
conditions. Tight binding condition refers to the situation where the determined IC50 goes down 
to the half of the concentration of the total kinase present in the solution. The higher the 
concentration of the probe, the harder it is for the inhibitor to displace the probe from the 
complex with the protein kinase – this would lead to the higher value of IC50. 
Unfortunately, several pilot experiments showed that the Hill slope of the curve was below 0.5 
and the displacement curve had several inconspicuous plateaus. The figure below (Figure 7) is 
an example. An interesting phenomenon occurred if the displacement assays at different 
conditions were compared. The higher the concentration of ARC-1182, the higher the TGL 
intensity at the lower plateau and the worse the shape of the curve. Such result could be caused 
by two processes. First, the incubation time might be too short (25 minutes), and the 
displacement of the probe from the complex is consequently not fully complete. Second, the 
probe could be simultaneously bound to the kinase and another compound. This interaction 
could result in lower Hill slope value and the absence of clearly distinguishable lower plateau. 
If the other compound also has the ability to fix the ARC-Lum in a way that it will emit TGL 
after excitation, the measurement window could be decreased. 
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Figure 7. Displacement curve of ARC-1411 at 50 nM ARC-1182 and 1 nM PKAc.  
4.1.1. Incubation Time 
As mentioned before, the high intensity level of the lower plateau might be due to the 
incomplete displacement reaction. Hence, the comparison of the curves incubated during 
different time spans was made (Figure 8). 
 
Figure 8. The study of different incubation times for a displacement assay, at 50 nM ARC-1182 and 1 nM PKAc. 
As it could be seen, the increase of the incubation time did not make distinguishable changes 
to the shape of the displacement curve, thus it could be stated, that 25 minutes of incubation 
time is sufficient for ARC-1411 to displace the ARC-1182 from the complex and short 
incubation time is not the reason that causes the problem described above.   
4.1.2. Nonspecific Binding of the ARC-Lum Probe 
Although normally the TGL signal should be produced only, if an ARC-Lum probe is in 
complex with the kinase, based on the shape of the previously described curve, there was a 
suspicion that ARC-Lum might form a complex with other components in the buffer in large 
excess compared to the kinase. Based on the properties of all substances in the 5-component 
buffer, BSA as a protein is the most probable compound to associate with ARC-Lum probe 
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leading to a TGL signal. BSA is used in the buffer to prevent PKAc and the probe from binding 
to the walls of the microplate wells and to protect PKAc from environmental damages (Xiao 
& Isaacs 2012). 
To study whether the interference came from the complex formed by BSA and ARC-1182, the 
displacement assays in the presence and absence of BSA were carried out (Figure 9). As it 
could be seen, although the shape of the curve was improved, the TGL signal of the higher 
plateau has also decreased by three-fold. Here, the question arises – whether BSA prevents the 
kinase and the probe from binding to the walls, or does it form complex with the ARC-Lum 
probe. 
 
Figure 9. Displacement assay with 5-component buffer and with 4-component buffer at 100 nM ARC-1182 and 
1 nM PKAc. Concentration of BSA was 7.5 µM.  
Based on these questions, several experiments were performed which are described in chapter 
3.6.2. Figure 10 A and Figure 10 B show the assay of dilution series of BSA with different 
concentration of ARC-1182. In Figure 10 A, the higher the concentration of BSA, the higher 
the TGL signal intensity when log[c(BSA)/M] is over approximately -6. It could be claimed 
that BSA and ARC-1182 formed a complex which gave the nonspecific TGL signal. When the 
concentration of BSA is below 1 µM, the effect of the binding is not obvious compared to 
higher BSA concentrations. In Figure 10 B, the fluorescence intensity was observed and it 
could be seen that at 100 nM ARC-1182 the fluorescence intensity was constant, indicating 
that the amount of the ARC-1182 in the solution is also constant. On the other hand, at 1 nM 
ARC-1182 a significant amount of the probe did not contribute to the fluorescence intensity – 
indicating its attachment to the walls. These results further prove the necessity of the presence 
of BSA in the assay buffer as an anti-adsorption agent. 
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A) B) 
 
Figure 10. A) The TGL intensity of dilution series of BSA with different concentrations of ARC-1182; B) The 
fluorescence intensity of dilution series of BSA with different concentrations of ARC-1182. In both graphs: 
green triangles – 100 nM ARC-1182, pink circles – 1 nM ARC-1182. 
In order to know at which concentration of ARC-1182 the TGL signal is less influenced by 
BSA, a dilution series of ARC-1182 at different concentrations of BSA was studied. Figure 11 
points to increased effect of BSA at higher than ~3 nM ARC-1182 concentrations. As it can be 
seen from the results of the study BSA at 1.5 µM concentration increases the signal less than 
at 7.5 µM concentration. 
 
Figure 11. Dilution series of ARC-1182 in the presence of 7.5 µM and 1.5 µM BSA. 
To establish the cause of the nonspecific association of BSA and ARC-1182, the comparison 
of behavior of two ARC-Lum probes ARC-1182 and ARC-1063 in assay conditions was 
carried out. ARC-1063 has almost the same structure as ARC-1182 but has a different dye 
attached to it. ARC-1063 is labeled with an Alexa Fluor 647 and ARC-1182 with a 
PromoFluor-647. As these two dyes have similar optical properties, ARC-1182 and ARC-1063 
have almost the same luminescence characteristics (Enkvist et al. 2011).  
The increase in the concentration of these two probes in the presence of BSA results in increase 
in the TGL intensity (Figure 12). The study revealed that ARC-1182 is more sensitive to the 
presence of BSA than ARC-1063. Thus it could be speculated that the association with BSA is 
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influenced by the structure of the dye. Nevertheless, as Alexa Fluor 647 is more expensive than 
PromoFluor-647, ARC-1182 was still consider to be a better candidate for HTS assays. 
 
Figure 12. The comparison of optical properties of ARC-1182 and ARC-1063 at different concentrations and in 
different assay buffers. 
To sum up the analysis of the influence of BSA, the following conclusions were made. Due to 
the high concentrations of ARC-1182 used in the analysis of high-affinity inhibitors, 1.5 µM 
BSA is recommended in order to avoid nonspecific TGL signal. Analysis where lower 
concentrations of ARC-1182 are used, 7.5 µM BSA is more suitable, as it helps to prevent the 
adsorption of the probe to the walls of the microplate wells and pipette tips. 
4.2. Analysis of the Parameters 
The ARC-Lum based TGL assay conditions were optimized for the analyses of inhibitors with 
different affinities towards PKAc. In order to evaluate the quality of the assay,the  following 
parameters were analyzed: the relative bias of Kd, relative SD of Kd, Z-factor, relative SD of 
data points, outliers and financial prominence. 
4.2.1. Analysis of Relative Bias of Kd 
The relative bias of Kd indicates the trueness of the assay. The influence of different 
concentrations of PKAc, ARC-1182 and ARC-1012 on Kd was studied. It was found, that the 
first point of the dilution series has the most significant influence on the bias (Figure 13). The 
higher the concentration the dilution series is started at, the lower is the bias. When the dilution 
series is started at lower concentrations, there are only a few points in the lower plateau. If any 
of them is deviating from the plateau, influence on the shape of the curve is more significant 
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than in case of greater number of points. The final Kd determined is thus more easily biased. 
The bias of the Kd is not effected by different concentrations of ARC-1182 and PKAc used. 
 
Figure 13. The relative bias of Kd values at different concentration level of inhibitors. Lower concentration of 
inhibitors are the average of relative bias of Kd of 80 µM of ARC-1012, 1 µM of ARC-904 and 5 µM of ARC-
1411. Middle concentration of inhibitors are the average of relative bias of Kd of 120 µM of ARC-1012, 4 µM of 
ARC-904 and mean of 20 µM and 40µM of ARC-1411. Higher concentration of inhibitors are the average of 
relative bias of Kd of 180 µM of ARC-1012, 8 µM of ARC-904 and 80 µM of ARC-1411.    
4.2.2. The Analysis of Relative SD of Kd  
The relative SD of Kd is a parameter, which estimates the repeatability – reflecting how much 
Kd values determined from parallel curves differ from each other. The influence of different 
concentrations of PKAc, ARC-1182 and ARC-1012 on the parameter was studied. The 
obtained results are similar to the previous deduction of the bias. The few deviations at the 
lower plateau points influence the determination of the affinity and thus SD. 
 
Figure 14. The relative SD of Kd values at different concentration level of inhibitors. Lower concentration of 
inhibitors are the average of relative SD of Kd of 80 µM of ARC-1012, 1 µM of ARC-904 and 5 µM of ARC-
1411. Middle concentration of inhibitors are the average of relative SD of Kd of 120 µM of ARC-1012, 4 µM of 
ARC-904 and 20 µM of ARC-1411. Higher concentration of inhibitors are the average of relative SD of Kd of 180 
µM of ARC-1012, 8 µM of ARC-904 and 40µM of ARC-1411.  
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4.2.3. The Analysis of Z-factor 
Z-factor is used to evaluate the robustness of the method via analysis of measurement window 
and the signal to noise ratio: the separation and the variation of upper and lower plateau values 
of displacement curves. A relationship between the assay window and Z-factor was described 
in the figure below (Figure 15). 
 
Figure 15. The relationship between Z-factor and assay window. 
Figure 15 shows that with the increase of the assay window, the Z-factor increases. When the 
measurement window is over 5, almost all of the determined Z-factors are over 0.5 
demonstrating excellent assay conditions. Appendix 3 describes the assay conditions, at which 
Z-factor is below 0.5 and the data reveals that when the concentration of ARC-1182 is more 
than 100 times higher than the concentration of PKAc, the Z-factor is quite small. This is due 
to two reasons. First, the low concentrations of PKAc leads to the low concentration of the 
complex, thus the TGL signal is low. Secondly, the large amount of ARC-1182 in excess tends 
to form a complex with BSA, thus resulting in high background signal and higher sensitivity 
towards errors. 
4.2.4. The Analysis of Relative SD of Data Points 
Relative SD of data points is also used to estimate the repeatability, the difference of this 
parameter to relative SD of Kd is that this parameter estimates the variation between each data 
point at same conditions. 
The analysis of relative SD of data points revealed that in case of ARC-904 and ARC-1012 
(Figure 16) the lower the concentrations of the kinase and the probe, the higher is the relative 
SD of the data points. This could be caused by the nonspecific binding of the substances to the 
0
0,2
0,4
0,6
0,8
1
0 20 40 60 80
Z
-f
ac
to
r
Assay window
Z=0.5
31 
 
walls of the pipette tip or the microplate well. The lower the concentration of the substance the 
higher proportion of it is adsorbed. There were no significant trends in the SD in case of ARC-
1411. 
 
Figure 16. The average of relative SD of data points of ARC-904 and ARC-1012 assays in case of different 
concentrations of PKAc and ARC-1182. 
4.2.5. The Analysis of Outliers 
Outlier analysis expresses the robustness of the assay. This parameter does not only depend on 
the assay conditions, but also on the operator and devices. Hence, only 5% of weightage was 
given to the parameter. 
The result shows that in case of ARC-1411 (Figure 17), the number of outliers increases if the 
concentration of PKAc decreases and the concentration of ARC-1182 increases. However, in 
case of ARC-904 and ARC-1012 (Figure 18), the number of outliers increases when the 
concentration of the ARC-1182 and PKAc decreases. Interestingly, in ARC-1411 assays the 
outliers were positioned throughout the displacement curve. In contrast, in the assays of 
relatively lower affinity inhibitors (ARC-904 and ARC-1012) the outliers were more bunched 
together to the lower plateau. In case of ARC-1411, there is a large amount of the probe in 
excess, which is eager to bind to the BSA. The errors in pipetting e.g. the buffer (and 
consequently BSA), are immediately reflected in the TGL signal intensity. The outliers in the 
lower plateau of the ARC-904 and ARC-1012 displacement curves are mostly likely caused by 
the low signal to noise ratio. 
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Figure 17. The average number of outliers in ARC-1411 assay in case of different concentrations of PKAc and 
ARC-1182. 
 
Figure 18. The average number of outliers in ARC-904 and ARC-1012 assay in case of different concentrations 
of PKAc and ARC-1182. 
4.2.6. Financial Prominence 
The financial prominence takes into account the cost of the compounds used in the 
displacement assays based on the marketing price. Understandably, the higher the amount of 
substances used in the assay, the more expensive it is. In case of ARC-1411 (Figure 19), the 
most critical factor influencing the price was the high concentration of ARC-1182 needed. 
Although high concentrations of the ARC-1411 were also used, the latter did not affect the 
overall price so much, as the probe ARC-1182 is much more expensive due to the price of the 
dye attached to it. In case of ARC-1012 (Figure 19), low concentrations of the probe and kinase 
were used, but as it was not as affine inhibitor as the probe itself, the higher concentrations of 
it were needed in order to obtain the full displacement curve. Thus the main influence on the 
price, when the Kd of the inhibitor is more than 10 times higher than the one of the probe, is 
the amount of inhibitor used. As in case of ARC-904 the Kd is around subnanomolar, the low 
concentrations of the inhibitor, the kinase and the inhibitor were used. 
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Figure 19. The influence on the score of economical estimation of ARC-1182 in ARC-1411 assays and of ARC-
1012 in ARC-1012 assays. 
4.3. The Optimal Conditions for ARC-Lum Based Assay 
ARC-1012, ARC-904 and ARC-1411 were chosen to represent the inhibitors which possess 
low nanomolar, subnanomolar and picomolar affinity towards PKAc, respectively. The optimal 
conditions were determined based on the analysis of all of the parameters by calculating the 
total score (Appendixes 4-6). It should be noted, that in case of low picomolar inhibitors, higher 
concentrations of the probe should be used in order to avoid the tight-binding conditions. In 
case of nanomolar inhibitors, the dilution series should be started at higher concentrations in 
order to obtain a complete displacement curve. 
Table 6. The optimal conditions for tested inhibitors 
 Reference Kd value (SD) Optimal condition 
ARC-1012  2.5 (0.8) nM 0.1 nM PKAc; 1nM ARC-
1182; 180 µM ARC-1012 
ARC-904  0.22 (0.04) nM 0.5 nM PKAc; 0.1 nM ARC-
1182; 4 µM ARC-904 
ARC-1411  0.008 (0.002) nM 0.5 nM PKAc; 10 nM ARC-
1182; 20 µM ARC-1411 
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Summary 
 
The aim of this master’s thesis was the determination of optimal conditions for ARC-Lum 
based time-gated photoluminescence measurements to determine the affinity of protein kinase 
inhibitors. 
Firstly, the optimal composition of the measurement buffer was established. The analysis 
revealed that due to the origin of the dye attached to the ARC-1182, the probe binds non-
specifically to BSA at higher concentrations. Simultaneously, results of the measurements 
pointed to the necessity of presence of BSA protein as an anti-adsorption agent in the assay 
buffer if ARC-1182 probe was applied at lower concentrations. Consequently, adequate 
concentration of BSA was established to achieve a minimal non-specific TGL signal and 
minimal adsorption of the probe and protein on walls of the microplate and pipette tips. 
Secondly, the relevance of different assay conditions was analysed based on six parameters. 
The results revealed that too low starting concentration of the inhibitor in the dilution series 
was the prominent reason to cause the bias of Kd values and high relative SD of Kd. The latter 
phenomenon was most likely caused by the incompleteness of the displacement curve. The Z-
factor and the number of outliers were mostly affected by the concentration ratio of ARC-1182 
and PKAc. If the probe was used in large excess, the TGL signal was sensitive towards non-
specific binding of BSA to the ARC-Lum probe. On the other hand, the lower concentrations 
of the probe and the kinase caused higher signal to noise ratio. The cost of the assay was mainly 
prescribed by the affinity of the inhibitors: in case of very high affinity inhibitors, the amount 
of the probe was the critical factor; in case of low-affinity inhibitors, the amount of the inhibitor 
was the determining factor. 
In this thesis, approximately 8000 analytical data points were processed for optimization 
of the ARC-Lum based TGL assay. The results obtained can be applied for the development 
of ARC-Lum probes and for determination of affinity of inhibitors in drug development process. 
Furthermore, the thesis offers valuable information for further adaption of the assay format to 
measurements in biological matrixes, for example cell lysates and bodily fluids. 
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ARC-Lum sondidel põhinev aeg-lahutatud fotoluminestsentsmeetodi 
optimeerimine kinaasiinhibiitorite afiinsuse määramiseks 
Shanshan Wu 
Kokkuvõte 
Käesoleva töö eesmärgiks oli optimeerida aeglahutatud fotoluminestsentsmeetodi tingimusi 
kinaasiinhibiitorite afiinsuse hindamiseks kolme erineva inhibiitori näite põhjal. Töös 
analüüsiti ligi 8000 katsepunkti, mille käigus optimeeriti puhvri koostisosad, määrati erinevate 
inhibiitorite afiinsuse hindamiseks optimaalseimad tingimused ja vaadeldi, kuidas kinaasi, 
sondi ja inhibiitori kontsentratsioonid mõjutavad erinevaid meetodi kvaliteeti kirjeldavaid 
parameetreid. 
Esmalt optimeeriti puhvri komponentide sisaldus. Katsete tulemusena selgus, et ARC-1182 
assotsieerub BSA-ga mittespetsiifiliselt, mille tulemusena emiteerub proovi ergastamisel pika 
eluealist luminestsentssignaali. Samuti tehti kindlaks, et madalatel sondi kontsentratsioonidel 
on BSA vajalik, et vältida sondi seostumist mikroplaadile ja pipetiotsikutele. Vastavalt saadud 
tulemustele kasutati kõrgetel sondi kontsentratsioonidel madalamat BSA kontsentratsiooni ja 
madalatel sondi kontsentratsioonidel kõrgemat BSA kontsentratsiooni. 
Järgmisena võrreldi erinevaid katsetingimusi meetodi kvaliteedi kirjeldavate paremeetrite 
alusel. Selgus, et kui inhibiitori lahjendusseeriat alustada selle liiga madalalt 
kontsentratsioonilt, ei moodustu täielikku sidumiskõverat, mis omakorda suurendab mõõteviga  
ja standardhälvet. Kõrge ARC-1182 ja PKAc kontsentratsioonide suhe mõjutab negatiivselt Z-
fakorit ja kõrvalekalduvate punktide arvu. Viimane on arvatavasti põhjustatud aeg-lahutusega 
luminestsentsmeetodi tundlikkusest mittespetsiifilise seostumise suhtes BSAga, kui sondi 
kontsentratsioon on üle 100 korra kõrgem kui kinaasi kontsentratsioon. Olukorras, kui kinaasi 
ja sondi kontsentratsioonid on väga madalad, on signaal-müra suhe madal ja kõrvalekalduvate 
punktide arv keskmisest suurem. 
Töö raames analüüsiti ka katsetingimuste finantsilist osakaalu. Selgus, et madalamate 
afiinsustega inhibiitorite analüüsimisel oli kõige kulukamaks faktoriks kõrge sondi 
kontsentratsioon, madalamate afiinsustega inhibiitorite analüüsimisel aga kõrge inhibiitori 
kontsentratsioon. 
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Töö tulemusi on võimalik kasutada uute ARC-Lum sondide arendusel ja samuti erinevate 
inhibiitorite afiinsuste määramiseks. Antud töö käigus omandati väärtuslikku informatsiooni, 
mille abil on võimalik antud meetodit tulevikus rakendada ka erinevates bioloogilistes 
maatriksites. 
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Appendixes 
Appendix 1. Structures of ARCs used in this work 
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Appendix 2. The 8-channel Automatic Pipette Analysis 
20 µl of 1 µM Bodipy FL was pipetted in the well of a microplate by using multi-dispensing 
mode with 3 replicate measurements (Figure A1). The microplate was incubated at 30 ºC with 
simultaneous shaking at 300 rpm, for 10 minutes and then measured with the microplate reader 
with fluorescence intensity optical module [excitation at 485 (12) nm, emission at 520 (15) 
nm]. The normality (Table A1) was analyzed and homogeneity test (Table A2) of channels 
based on the data obtained was done.  
 
Figure A 1. The fluorescence intensity assay for multi-dispensing mode. 
Table A 1. Test of normality of all of the intensity points 
Shapiro-Wilk 
Statistic Degree of freedom Probability 
0.963 24 0.512 
Table A 2. Test of homogeneity of variances of intensity points of channels 
Levene Statistic Degree of freedom 1 Degree of freedom 2 Probability 
2.105 7 16 0.103 
The Shapiro-Wik’s test (Shapiro & Wilk 1965) (p=0.512) showed that the data from each 
channel are approximately normally distributed. Therefore, the parametric Levene’s test (Deng 
et al. 2014) was applied which verified the quality of variances in the sample (homogeneity of 
variance) and the test showed that the probability is 0.103, which is bigger than 0.05, meaning 
there is no significant difference between channels.   
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Appendix 3. The Assay Conditions Where the Z-factor was Below 0.5 
Condition Z-factor Assay window 
0.1 nM PKAc; 80nM ARC-1182; 80 µM ARC-1411 0.103 2.362 
0.1 nM PKAc; 80nM ARC-1182; 80 µM ARC-1411 0.123 2.360 
0.1 nM PKAc; 10 nM ARC-1182; 5 µM ARC-1411 0.253 3.153 
0.1 nM PKAc; 80nM ARC-1182; 20 µM ARC-1411 0.297 1.862 
0.1 nM PKAc; 40 nM ARC-1182; 80 µM ARC-1411 0.326 3.014 
0.1 nM PKAc; 80nM ARC-1182; 5 µM ARC-1411 0.341 1.474 
0.1 nM PKAc; 80nM ARC-1182; 20 µM ARC-1411 0.360 1.817 
1nM PKAc; 0.1 nM ARC-1182; 1 µM ARC-904 0.379 6.568 
0.1 nM PKAc; 40 nM ARC-1182; 80 µM ARC-1411 0.383 2.939 
0.1 nM PKAc; 40 nM ARC-1182; 20 µM ARC-1411 0.393 2.168 
0.1 nM PKAc; 80nM ARC-1182; 5 µM ARC-1411 0.398 1.505 
0.1 nM PKAc; 80nM ARC-1182; 80 µM ARC-1411 0.403 2.525 
0.1 nM PKAc; 40 nM ARC-1182; 5 µM ARC-1411 0.412 1.837 
0.1 nM PKAc; 80nM ARC-1182; 20 µM ARC-1411 0.415 1.955 
0.1 nM PKAc; 40 nM ARC-1182; 20 µM ARC-1411 0.416 1.985 
0.1 nM PKAc; 1nM ARC-1182; 1 µM ARC-904 0.438 3.670 
0.1 nM PKAc; 40 nM ARC-1182; 20 µM ARC-1411 0.446 2.129 
0.1 nM PKAc; 80nM ARC-1182; 5 µM ARC-1411 0.447 1.524 
0.1 nM PKAc; 40 nM ARC-1182; 80 µM ARC-1411 0.458 3.100 
0.1 nM PKAc; 1nM ARC-1182; 1 µM ARC-904 0.495 3.948 
0.5 nM PKAc; 80 nM ARC-1182; 40 µM ARC-1411 0.496 3.178 
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Appendix 4. The Determination of Optimal Conditions for Measurements with 
ARC-1012  
Assay 
conditions 
Kd 
(SDmean); 
(nM) 
Weight 
score 
of 
relative 
bias  
Z-factor Weight 
score 
Relative 
SD of 
data 
points(%) 
Weight 
score 
Outlier Weight 
score 
Relative 
SD of Kd 
(%) 
Weight 
score 
Economic 
Weight 
score 
Total 
score 
1nM PKAc; 
1 nM ARC-
1182; 80 
µM ARC-
1012 
3.1 (0.3) 22.91 0.90 13.46 3.9 14.41 0 5.00 17.7 12.35 18.55 86.68 
1nM PKAc; 
0.5 nM 
ARC-1182; 
80 µM 
ARC-1012 
3.6 (0.6) 16.43 0.89 13.30 9.7 13.54 1 4.50 30.6 10.14 18.63 76.8 
1nM PKAc; 
0.1 nM 
ARC-1182; 
80 µM 
ARC-1012 
0.9(0.4) 11.34 0.88 13.13 27.4 10.89 3 3.50 69.4 4.58 18.69 62.13 
0.5 nM 
PKAc; 1nM 
ARC-1182; 
80 µM 
ARC-1012 
2.8 (0.8) 26.08 0.85 12.79 7.4 13.89 1 4.50 47.6 7.86 18.60 83.73 
0.5 nM 
PKAc; 0.5 
nM ARC-
1182; 80 
µM ARC-
1012 
2.0 (1.1) 
 
24.31 0.86 12.89 16.9 12.46 0 5.00 97.3 0.40 18.68 73.74 
0.5 nM 
PKAc; 0.1 
nM ARC-
1182; 80 
µM ARC-
1012 
2.9 (0.1) 25.45 0.87 13.11 16.2 12.58 1 4.50 7.9 13.82 18.74 88.19 
0.1 nM 
PKAc; 1nM 
ARC-1182; 
80 µM 
ARC-1012 
2.3 (0.7) 27.58 0.74 11.10 8.9 13.66 4 3.00 56.4 6.55 18.64 80.52 
0.1 nM 
PKAc; 0.5 
nM ARC-
1182; 80 
µM ARC-
1012 
5.4 (1.1) -5.4 0.82 12.37 11.3 13.31 5 2.50 35.9 9.62 18.72 51.11 
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1nM PKAc; 
1 nM ARC-
1182; 120 
µM ARC-
1012 
1.9 (0.2) 23.14 0.86 12.93 3.4 14.49 0 5.0 15.3 12.71 17.95 86.22 
1nM PKAc; 
0.5 nM 
ARC-1182; 
120 µM 
ARC-1012 
1.4 (0.4) 17.31 0.84 12.66 9.8 13.53 0 5.0 42.5 8.62 18.03 75.15 
1nM PKAc; 
0.1 nM 
ARC-1182; 
120 µM 
ARC-1012 
0.9 (0.1) 10.59 0.86 12.93 10.5 13.42 1 4.5 28.1 10.79 18.09 70.32 
0.5 nM 
PKAc; 1nM 
ARC-1182; 
120 µM 
ARC-1012 
1.6 (0.1) 19.19 0.90 13.49 5.7 14.15 0 5.0 13.6 12.97 18.00 82.79 
0.5 nM 
PKAc; 0.5 
nM ARC-
1182; 120 
µM ARC-
1012 
2.1 (0.3) 25.72 0.87 13.07 5.8 14.13 0 5.0 26.9 10.97 18.08 86.96 
0.5 nM 
PKAc; 0.1 
nM ARC-
1182; 120 
µM ARC-
1012 
0.8 (0.1) 9.22 0.85 12.82 22.5 11.62 3 3.5 25.7 11.15 18.14 66.44 
0.1 nM 
PKAc; 1nM 
ARC-1182; 
120 µM 
ARC-1012 
3.1 (0.3) 22.85 0.86 12.87 3.5 14.47 3 3.5 19.2 12.12 18.04 83.85 
0.1 nM 
PKAc; 0.5 
nM ARC-
1182; 120 
µM ARC-
1012 
2.3 (0.1) 27.74 0.78 11.77 6.4 14.03 1 4.5 3.9 14.42 18.12 90.57 
0.1 nM 
PKAc; 0.1 
nM ARC-
1182; 120 
µM ARC-
1012 
3.1 (0.1) 23.24 0.86 12.93 12.1 13.18 2 4.0 5.4 14.19 18.18 85.71 
 
1nM PKAc; 
1 nM ARC-
1182; 180 
µM ARC-
1012
  
 
 
3.2 (0.4) 
 
 
21.07 
 
 
0.89 
 
 
13.41 
 
 
5.0 
 
 
14.24 
 
 
0 
 
 
5.0 
 
 
20.2 
 
 
11.96 
 
 
17.05 
 
 
82.74 
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1nM PKAc; 
0.5 nM 
ARC-1182; 
180 µM 
ARC-1012 
2.8 (0.1) 26.52 0.92 13.76 4.3 14.36 1 4.5 9.1 13.64 17.13 89.90 
1nM PKAc; 
0.1 nM 
ARC-1182; 
180 µM 
ARC-1012 
1.7 (0.1) 20.51 0.85 12.73 13.3 13.01 2 4.0 8.9 13.66 17.19 81.09 
0.5 nM 
PKAc; 1nM 
ARC-1182; 
180 µM 
ARC-1012 
2.5 (0.1) 29.35 0.82 12.27 9.4 13.58 0 5.0 5.7 14.14 17.10 91.44 
0.5 nM 
PKAc; 0.5 
nM ARC-
1182; 180 
µM ARC-
1012 
2.5 (0.2) 29.78 0.86 12.92 6.0 14.11 2 4.0 13.7 12.95 17.18 90.93 
0.5 nM 
PKAc; 0.1 
nM ARC-
1182; 180 
µM ARC-
1012 
1.9 (0.2) 22.24 0.94 14.06 18.0 12.30 0 5.0 22.4 11.64 17.24 82.47 
0.1 nM 
PKAc; 1nM 
ARC-1182; 
180 µM 
ARC-1012 
2.4 (0.1) 29.18 0.82 12.27 4.5 14.32 1 4.5 3.7 14.44 17.14 91.85 
0.1 nM 
PKAc; 0.5 
nM ARC-
1182; 180 
µM ARC-
1012 
2.4 (0.4) 28.32 0.77 11.55 10.6 13.41 0 5.0 32.2 10.17 17.22 85.67 
0.1 nM 
PKAc; 0.1 
nM ARC-
1182; 180 
µM ARC-
1012 
1.2 (0.1) 13.99 0.85 12.73 19.6 12.07 1 4.5 13.2 13.02 17.28 73.58 
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Appendix 5. The Estimation of Optimal Conditions for ARC-904 
Assay 
conditions 
Kd 
(SDmean); 
(nM) 
Weight 
score 
of 
relative 
bias  
Z-
factor 
Weight 
score 
Relative 
SD of 
data 
points(%) 
Weight 
score 
Outlier Weight 
score 
Relative 
SD of Kd 
(%) 
Weight 
score 
Economic 
Weight 
score 
Total 
score 
1nM PKAc; 1 
nM ARC-1182; 
1 µM ARC-904 
0.218 
(0.013) 
29.97 0.74 11.06 4.5 14.32 1 4.50 10 13.44 14.70 87.99 
1nM PKAc; 0.5 
nM ARC-1182; 
1 µM ARC-904 
0.169 
(0.009) 
23.27 0.67 10.05 6.0 14.10 0 5.00 19 12.19 16.20 80.81 
1nM PKAc; 0.1 
nM ARC-1182; 
1 µM ARC-904 
0.148 
(0.017) 
20.46 0.52 7.80 5.8 14.12 1 4.50 29 10.64 17.40 74.92 
0.5 nM PKAc; 
1nM ARC-
1182; 1 µM 
ARC-904 
0.100 
(0.011) 
13.87 0.80 11.94 5.1 14.23 0 5.00 8.7 13.69 15.70 74.43 
0.5 nM PKAc; 
0.5 nM ARC-
1182; 1 µM 
ARC-904 
0.164 
(0.020) 
 
22.60 0.72 10.80 5.0 14.24 0 5.00 21 11.83 17.20 81.67 
0.5 nM PKAc; 
0.1 nM ARC-
1182; 1 µM 
ARC-904 
0.1280 
(0.003) 
17.64 0.56 8.45 4.9 14.26 2 4.00 20 11.96 18.40 74.70 
0.1 nM PKAc; 
1nM ARC-
1182; 1 µM 
ARC-904 
0.39 
(0.066) 
5.99 0.58 8.70 5.7 14.15 2 4.00 20 12.04 16.50 61.38 
0.1 nM PKAc; 
0.5 nM ARC-
1182; 1 µM 
ARC-904 
0.310 
(0.036) 
17.33 0.82 12.35 4.8 14.29 3 3.50 4.2 14.38 18.00 79.84 
0.1 nM PKAc; 
0.1 nM ARC-
1182; 1 µM 
ARC-904 
0.313 
(0.042) 
16.94 0.71 10.68 6.2 14.08 4 3.00 23 11.52 19.20 75.42 
1nM PKAc; 1 
nM ARC-1182; 
4 µM ARC-904 
0.35 
(0.060) 
11.24 0.79 11.82 4.4 14.34 0 5.0 29 10.59 13.80 66.79 
1nM PKAc; 0.5 
nM ARC-1182; 
4 µM ARC-904 
0.179 
(0.010) 
24.65 0.81 12.08 2.8 14.58 0 5.0 10 13.48 15.30 85.09 
1nM PKAc; 0.1 
nM ARC-1182; 
4 µM ARC-904 
0.133 
(0.005) 
18.32 0.85 12.75 4.8 14.28 0 5.0 6.0 14.10 16.50 80.95 
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0.5 nM PKAc; 
1nM ARC-
1182; 4 µM 
ARC-904 
0.252 
(0.016) 
25.29 0.85 12.68 4.6 14.31 2 4.0 11 13.37 14.80 84.44 
0.5 nM PKAc; 
0.5 nM ARC-
1182; 4 µM 
ARC-904 
0.375 
(0.016) 
8.35 0.79 11.91 3.5 14.48 0 5.0 7.6 13.86 16.30 69.90 
0.5 nM PKAc; 
0.1 nM ARC-
1182; 4 µM 
ARC-904 
0.228 
(0.011) 
28.60 0.76 11.40 6.7 13.99 2 4.0 8.6 13.71 17.50 89.19 
0.1 nM PKAc; 
1nM ARC-
1182; 4 µM 
ARC-904 
0.281 
(0.029) 
21.30 0.72 10.80 6.2 14.08 1 4.5 18 12.31 15.50 78.58 
0.1 nM PKAc; 
0.5 nM ARC-
1182; 4 µM 
ARC-904 
0.195 
(0.023) 
26.86 0.77 11.58 10.4 13.44 0 5.0 20 11.99 17.10 85.97 
0.1 nM PKAc; 
0.1 nM ARC-
1182; 4 µM 
ARC-904 
0.29 
(0.069) 
20.06 0.76 11.36 15.6 12.65 1 4.5 41 8.78 18.30 75.64 
1nM PKAc; 1 
nM ARC-1182; 
8 µM ARC-
904
  
0.238 
(0.007) 
27.22 0.75 11.30 1.7 14.75 0 5.0 5.5 14.18 12.60 85.04 
1nM PKAc; 0.5 
nM ARC-1182; 
8 µM ARC-904 
0.234 
(0.024) 
27.77 0.86 12.93 8.4 13.75 0 5.0 18 12.33 14.10 85.88 
1nM PKAc; 0.1 
nM ARC-1182; 
8 µM ARC-904 
0.130 
(0.016) 
17.91 0.86 12.90 3.6 14.46 0 5.0 21 11.89 15.30 77.45 
0.5 nM PKAc; 
1nM ARC-
1182; 8 µM 
ARC-904 
0.138 
(0.011) 
19.01 0.75 11.25 3.0 14.56 0 5.0 13 13.02 13.60 76.43 
0.5 nM PKAc; 
0.5 nM ARC-
1182; 8 µM 
ARC-904 
0.159 
(0.016) 
21.90 0.82 12.26 3.2 14.52 0 5.0 18 12.33 15.10 81.11 
0.5 nM PKAc; 
0.1 nM ARC-
1182; 8 µM 
ARC-904 
0.221 
(0.031) 
29.56 0.76 11.39 3.8 14.43 0 5.0 24 11.36 16.30 88.03 
0.1 nM PKAc; 
1nM ARC-
0.198 
(0.016) 
27.27 0.83 12.42 3.6 14.46 0 5.0 14 12.88 14.40 86.42 
53 
 
1182; 8 µM 
ARC-904 
0.1 nM PKAc; 
0.5 nM ARC-
1182; 8 µM 
ARC-904 
0.185 
(0.014) 
25.48 0.77 11.58 4.2 14.37 0 5.0 13 13.03 15.90 85.36 
0.1 nM PKAc; 
0.1 nM ARC-
1182; 8 µM 
ARC-904 
0.148 
(0.018) 
20.39 0.80 12.00 5.6 14.16 1 4.5 21 11.89 17.10 85.04 
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Appendix 6. The Estimation of Optimal Conditions for ARC-1411 
Assay 
conditions 
Kd 
(SDmean)
; (nM) 
Weight 
score of 
relative 
bias  
Z-
facto
r 
Weig
ht 
score 
Relativ
e SD of 
data 
points(
%) 
Weigh
t score 
Outlie
r 
Weight 
score 
Relative 
SD of Kd 
(%) 
Weight 
score 
Economic 
Weight 
score 
Total 
score 
1nM PKAc; 80 
nM ARC-1182; 
5 µM ARC-
1411 
0.0045 
(0.0003) 
15.89 0.69 10.39 2.4 14.64 0 5.0 12.9 13.07 10.08 69.07 
1nM PKAc; 40 
nM ARC-1182; 
5 µM ARC-
1411 
0.0036 
(0.0003) 
12.86 0.88 13.17 2.6 14.61 0 5.0 15.6 12.65 14.88 73.17 
1nM PKAc; 10 
nM ARC-1182; 
5 µM ARC-
1411 
0.0049 
(0.0011) 
17.28 0.90 13.53 6.5 14.03 1 4.5 39.8 9.03 18.48 76.85 
0.5 nM PKAc; 
80nM ARC-
1182; 5 µM 
ARC-1411 
0.0066 
(0.0012) 
23.51 0.65 9.73 5.0 14.25 3 3.5 31.0 10.36 10.12 71.46 
0.5 nM PKAc; 
40 nM ARC-
1182; 5 µM 
ARC-1411 
0.0046 
(0.0005) 
16.53 0.64 9.53 2.5 14.63 2 4.0 20.1 11.98 14.92 71.59 
0.5 nM PKAc; 
10 nM ARC-
1182; 5 µM 
ARC-1411 
0.0043 
(0.0002) 
15.43 0.88 13.20 3.1 14.54 1 4.5 8.5 13.73 18.52 79.91 
0.1 nM PKAc; 
80nM ARC-
1182; 5 µM 
ARC-1411 
0.0245 
(0.0128) 
-27.43 0.40 5.93 2.4 14.63 7 1.5 90.2 1.47 10.15 6.26 
0.1 nM PKAc; 
40 nM ARC-
1182; 5 µM 
ARC-1411 
0.0086 
(0.0016) 
29.29 0.52 7.81 1.7 14.75 6 2.0 32.8 10.09 14.95 78.89 
0.1 nM PKAc; 
10 nM ARC-
1182; 5 µM 
ARC-1411 
0.0069 
(0.0008) 
24.58 0.55 8.25 3.5 14.47 2 4.0 20.2 11.97 18.55 81.81 
1nM PKAc; 80 
nM ARC-1182; 
20 µM ARC-
1411 
0.0066 
(0.0003) 
23.51 0.88 13.17 3.6 14.47 0 5.0 7.8 13.82 9.84 79.82 
1nM PKAc; 40 
nM ARC-1182; 
20 µM ARC-
1411 
0.0076 
(0.0011) 
27.08 0.83 12.47 10.8 13.38 2 4.0 25.3 11.21 14.64 82.77 
1nM PKAc; 10 
nM ARC-1182; 
20 µM ARC-
1411 
0.022 
(0.0018) 
-17.20 0.92 13.82 7.6 13.86 0 5.0 14.7 12.80 18.24 46.52 
0.5 nM PKAc; 
80nM ARC-
1182; 20 µM 
ARC-1411 
0.0061 
(0.0006) 
21.73 0.75 11.28 3.3 14.50 1 4.5 16.7 12.50 9.88 74.39 
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0.5 nM PKAc; 
40 nM ARC-
1182; 20 µM 
ARC-1411 
0.011 
(0.0006) 
19.21 0.79 11.79 3.9 14.42 0 5.0 9.3 13.61 14.68 
 
78.71 
0.5 nM PKAc; 
10 nM ARC-
1182; 20 µM 
ARC-1411 
0.0078 
(0.0007) 
27.79 0.80 12.05 9.6 13.56 0 5.0 16.1 12.59 18.28 89.26 
0.1 nM PKAc; 
40 nM ARC-
1182; 20 µM 
ARC-1411 
0.0085 
(0.0015) 
29.68 0.42 6.28 4.9 14.27 5 2.5 29.8 10.53 14.71 77.97 
0.1 nM PKAc; 
10 nM ARC-
1182; 20 µM 
ARC-1411 
0.010 
(0.0018) 
23.59 0.75 11.18 6.1 14.08 5 2.5 29.8 10.53 18.31 80.19 
1nM PKAc; 80 
nM ARC-1182; 
40 µM ARC-
1411 
0.0096 
(0.0011) 
25.69 0.60 8.94 2.7 14.59 0 5.0 20.1 11.98 9.36 75.57 
1nM PKAc; 40 
nM ARC-1182; 
40 µM ARC-
1411
  
0.0041 
(0.0006) 
14.54 0.85 12.70 3.0 14.55 0 5.0 23.5 11.48 14.16 
72.42 
1nM PKAc; 10 
nM ARC-1182; 
40 µM ARC-
1411 
0.0043 
(0.0005) 
15.43 0.93 13.90 5.1 14.24 0 5.0 19.0 12.15 17.76 78.48 
0.5 nM PKAc; 
80nM ARC-
1182; 40 µM 
ARC-1411 
0.0111 
(0.0012) 
20.31 0.64 9.55 4.0 14.40 6 2.0 18.8 12.18 9.40 67.83 
0.5 nM PKAc; 
40 nM ARC-
1182; 40 µM 
ARC-1411 
0.0027 
(0.0002) 
9.51 0.71 10.64 7.3 13.91 1 4.5 14.1 12.89 14.20 65.65 
0.5 nM PKAc; 
10 nM ARC-
1182; 40 µM 
ARC-1411 
0.0015 
(0.00001
) 
5.31 0.79 11.92 13.8 12.93 0 5.0 1.4 14.79 17.80 67.74 
1nM PKAc; 80 
nM ARC-1182; 
80 µM ARC-
1411 
0.01142 
(0.0013) 
19.31 0.86 12.91 2.8 14.59 1 4.5 19.7 12.04 9.36 72.72 
1nM PKAc; 40 
nM ARC-1182; 
80 µM ARC-
1411 
0.01249 
(0.0008) 
15.50 0.82 12.28 3.6 14.46 0 5.0 10.6 13.42 14.16 74.82 
1nM PKAc; 10 
nM ARC-1182; 
80 µM ARC-
1411 
0.01174 
(0.0006) 
18.17 0.84 12.65 5.1 14.24 0 5.0 9.0 13.65 17.76 81.48 
0.5 nM PKAc; 
80nM ARC-
1182; 80 µM 
ARC-1411 
0.01154 
(0.0013) 
18.89 0.77 11.52 3.4 14.49 0 5.0 19.8 12.03 9.40 71.33 
0.5 nM PKAc; 
40 nM ARC-
1182; 80 µM 
ARC-1411 
0.00743  
(0.0013) 
26.47 0.74 11.04 4.1 14.39 2 4.0 31.2 10.32 14.20 80.43 
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0.5 nM PKAc; 
10 nM ARC-
1182; 80 µM 
ARC-1411 
0.00812 
(0.0021) 
28.93 0.85 12.68 10.0 13.50 0 5.0 44.2 8.37 17.80 86.27 
0.1 nM PKAc; 
10 nM ARC-
1182; 80 µM 
ARC-1411 
0.1087 
(0.0023) 
21.27 0.66 9.94 4.1 14.38 0 5.0 36.1 9.59 17.83 78.01 
 
